SynthesisThe Indian journal of medical research2025
Risk of gynaecologic cancers in women with metabolic syndrome: A systematic review & meta-analysis.
Synthesis in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence of late presentation of HIV among older adults in Asia: a systematic review and meta-analysis protocol.Systematic reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives Metabolic syndrome may be associated with the risk of gynaecological cancers. This systematic review aims to evaluate the risk of gynaecological cancers among women with metabolic syndrome. Methods Studies published in English using a search strategy across PubMed, Google Scholar, and Scopus were identified from the earliest available indexing of the respective databases up to September 12-14, 2023. After removing duplicates and conducting a detailed screening by two independent reviewers, 25 studies were identified. Critical appraisal was conducted using JBI checklists for case-control and cohort studies and AXIS checklist for cross-sectional studies. Data extraction was conducted for information pertaining to study design, participant demographics, definition of metabolic syndrome, reported summary measures and type of gynaecological cancer. Results Random effects models were employed separately for each study design, reported summary measures and the type of gynaecological cancers. In case-control, cross-sectional, and cohort studies, presence of metabolic syndrome was associated with uterine/endometrial cancer [odds ratio (OR) 1.99, P<0.01, OR 2.64, P<0.01, hazard ratio (HR) 1.45, P=0.04], respectively. Case-control and cohort studies in ovarian cancer suggested association (OR 3.44, P<0.01, OR 1.02, P=0.79, and HR 1.02, P=0.80). Cohort studies in cervical cancer patients, yielded HR 1.26, P=0.96 and adjusted HR 1.27, P=0.83. The critical appraisal of the included studies was high. GRADE reported low-quality evidence for cervical, uterine/endometrial, and ovarian cancer. Interpretation & conclusions Women with metabolic syndrome are associated with increased risk of gynaecological cancers regardless of study design, type of gynaecological cancer and definitions of metabolic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.